Andersson O K, Persson B, Widgren B R, Wysocki M
Department of Internal Medicine I, University of Gothenburg, Sweden.
J Cardiovasc Pharmacol. 1990;15 Suppl 1:S87-9.
Seventeen middle-aged males with sustained essential hypertension (WHO stage II) and diastolic blood pressures (BP) exceeding 100 mm Hg during a placebo run-in period completed a trial to assess the hemodynamic effects of isradipine, a new dihydropyridine calcium antagonist. The study was double-blind and placebo-controlled with a crossover design. Brachial artery compliance was assessed as the ratio of stroke volumes and simultaneous pulse pressure. During therapy with isradipine (all patients received 7.5 mg b.i.d.), highly significant reductions in supine systolic BP [from 184 +/- 16 to 162 +/- 20 mm Hg (mean +/- S.D.)] and diastolic BP (from 96 +/- 8 to 83 +/- 8 mm Hg) were observed. Heart rate was unchanged (69 +/- 3 vs. 73 +/- 2 beats/min) during chronic therapy. Total peripheral resistance was significantly reduced (from 24.8 +/- 9 to 17.4 +/- 5 units) while cardiac output was unchanged (6.0 +/- 1.9 vs. 7.2 +/- 1.8 L/min). Stroke volume was unchanged (92 +/- 25 vs. 100 +/- 25 ml/beat), and a significant (p less than 0.05) increase in brachial artery compliance (from 1.05 +/- 0.25 to 1.26 +/- 0.35 ml/mm Hg) was observed.
17名患有持续性原发性高血压（世界卫生组织II期）且在安慰剂导入期舒张压超过100 mmHg的中年男性完成了一项试验，以评估新型二氢吡啶类钙拮抗剂伊拉地平的血流动力学效应。该研究采用双盲、安慰剂对照的交叉设计。肱动脉顺应性通过每搏量与同时测量的脉压之比进行评估。在伊拉地平治疗期间（所有患者每日两次接受7.5 mg），观察到仰卧位收缩压[从184±16降至162±20 mmHg（均值±标准差）]和舒张压（从96±8降至83±8 mmHg）显著降低。慢性治疗期间心率未变（69±3次/分钟对73±2次/分钟）。总外周阻力显著降低（从24.8±9降至17.4±5单位），而心输出量未变（6.0±1.9对7.2±1.8 L/分钟）。每搏量未变（92±25对100±25 ml/次搏动），并且观察到肱动脉顺应性显著增加（从1.05±0.25增至1.26±0.35 ml/mmHg）（p<0.05）。
